Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
Rates of cardiovascular disease and diabetes are more than 2-fold greater in HIV infected
people than the general population. Protease inhibitor booster antiretroviral therapy
(PI-ART) which is used by ~50% of HIV infected people in the USA is an established risk
factor for diabetes. Tauroursodeoxycholic acid (TUDCA), a naturally occurring bile salt,
improves insulin sensitivity in HIV uninfected subjects, although the mechanisms for these
benefits are unclear. This study will explore the hypothesis that TUDCA will improve insulin
action in people with HIV who are receiving PI-ART. Further, this project will clarify the
molecular mechanisms responsible for these improvements potentially benefiting society,
irrespective of HIV status.
Phase:
N/A
Details
Lead Sponsor:
Washington University School of Medicine
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) National Institutes of Health (NIH)